Canagliflozin is under clinical development by johnson & johnson and currently in Phase III for Diastolic Heart Failure. According to GlobalData, Phase III drugs for Diastolic Heart Failure does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Canagliflozin LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Canagliflozin overview
Canagliflozin (Invokana/ Prominad/Canaglu/ Motivyst/Sulisent ) a drug of the gliflozin class and an antidiabetic drug. It is formulated as film-coated tablets for oral route of administration. It is indicated for the treatment of type 2 diabetes mellitus. It is also indicated for the use in combination with metformin and sitagliptin in adults with type 2 diabetes mellitus, and reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria 300 mg/day. Canaglu is indicated for the treatment of chronic kidney disease complicated with type 2 diabetes mellitus.
The drug candidate is under development for the treatment of heart failure with preserved ejection fraction in type 2 diabetes mellitus, symptomatic heart failure (HF) including heart failure with reduced ejection fraction [HFrEF] and heart failure with preserved ejection fraction [HFpEF], diabetic nephropathy. It was also under development for type 1 diabetes, cardiovascular disease in type 2 diabetes patients and obesity.
Johnson & Johnson overview
johnson & johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases; consumer products in oral care, baby care, beauty, over the counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, neurovascular care, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
For a complete picture of Canagliflozin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
